Back

Lipid Levels and CV Outcome with CETP Inhibition by Evacetrapib in the ACCELERATE Trial

28 August 2016 (14:30 - 14:45)
Organised by:
Congress Presentation Part of: Clinical Trial Update Prevention Primary cardiovascular prevention: interventions and outcomes ESC Premium Access ESC Congress 2016

About the speaker

Photo
Professor A Michael Lincoff

Cleveland Clinic Hospital, Cleveland (United States of America)

5 More presentations in this session

Presentation thumbnail
The influence of blinding and un-blinding on statin related adverse events (AEs): new evidence from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Associate Professor A. Gupta (London, GB)
Slides Video
Presentation thumbnail
Primary prevention of patients with high LDL-cholesterol levels greater than 4.9 mmol/l: analysis from the WOSCOPS trial
Doctor A. Vallejo-Vaz (Seville, ES)
Presentation thumbnail
The Benefit of Adding Ezetimibe to Statin Therapy in Patients With or Without prior Coronary Artery Bypass Graft surgery in the IMPROVE-IT Trial
Professor A. Eisen (Petah Tikva, IL)
Slides Video
Presentation thumbnail
First-in-man study of a pacemaker-mediated programmable hypertension control therapy
Professor P. Neuzil (Prague, CZ)
Slides Video
Presentation thumbnail
The relationship between severe hypoglycaemic events and cardiovascular outcomes is bidirectional: novel results from TECOS
Professor E. Standl (Munich, DE)

Access the full session

Session thumbnail
Clinical Trial Update Prevention

The Event

Event poster

ESC Congress 2016

28 August 2016 14:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources